CD44 cell adhesion molecules

Journal of Clinical Pathology - Molecular Pathology

Volumn 52, Issue 4, 1999, Pages 189-196

  Goodison, S ^a   Urquidi, V ^a   Tarin, D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alternative splicing; CD44 structure; Hyaluronic acid; Neoplasia

Indexed keywords

CELL ADHESION MOLECULE; COLLAGEN; FIBRONECTIN; HERMES ANTIGEN; HYALURONIC ACID; LAMININ; LIGAND; OSTEOPONTIN;

ALTERNATIVE RNA SPLICING; ANTIGEN EXPRESSION; CELL ADHESION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; LIGAND BINDING; NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR CELL;

EID: 0032768970     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.52.4.189     Document Type: Review

References (114)

1. Goodfellow PN, Banting G, Wiles MV, et al. The gene, MIC4, which controls expression of the antigen defined by monoclonal antibody F10.44.2, is on human chromosome 11. Eur J Immunol 1982;12:659-63.
2. Hofmann M, Rudy W, Zoller M, et al. CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res 1991;51:5292-7.
3. Dougherty GJ, Landorp PM, Cooper DL, et al. Molecular cloning of CD44R1 and CD44R2, two novel isoforms of the human CD44 lymphocyte "homing" receptor expressed by hemopoietic cells. J Exp Med 1991;174:1-5.
4. Tolg C, Hofmann M, Herrlich P, et al. Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acids Res 1993;21:1225-9.
5. Screaton GR, Bell MV, Jackson DG, et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992;89:12160-4.
6. Ermak G, Jennings T, Boguniewicz A, et al. Novel CD44 messenger RNA isoforms in human thyroid and breast tissues feature unusual sequence rearrangements. Clin Cancer Res 1996;2:1251-4.
7. Screaton GR, Bell MV, Bell JI, et al. The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat. J Biol Chem 1993;268:12235-8.
8. Goldstein LA, Butcher EC. Identification of mRNA that encodes an alternative form of H-CAM (CD44) in lymphoid and nonlymphoid tissues. Immunogenetics 1990;32:389-97.
9. Kohda D, Morton CJ, Parkar AA, et al. Solution structure of the link module: a hyaluronan-binding domain involved in extracellular matrix stability and cell migration. Cell 1996;86:767-75.
10. Bennett KL, Modrell B, Greenfield B, et al. Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J Cell Biol 1995;131:1623-33.
11. Jackson DG, Bell JI, Dickinson R, et al. Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J Cell Biol 1995;128:673-85.
12. Sleeman JP, Rahmsdorf U, Steffen A, et al. CD44 variant exon v5 encodes a tyrosine that is sulphated. Eur J Biochem 1998;255:74-80.
13. Yang B, Yang BL, Savant RC, et al. Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein. EMBO J 1994;13:286-96.
14. Liao HX, Lee DM, Levesque MC, et al. N-terminal and central regions of the human CD44 extracellular domain participate in cell surface hyaluronan binding. J Immunol 1995;155:3938-45.
15. Bajorath J, Greenfield B, Munro SB, et al. Identification of CD44 residues important for hyaluronan binding and delineation of the binding site. J Biol Chem 1998;273:338-43.
16. Peach RJ, Hollenbaugh D, Stamenkovic I, et al. Identification of hyaluronic acid binding sites in the extracellular domain of CD44. J Cell Biol 1993;122:257-64.
17. Lesley J, English N, Perschl A, et al. Variant cell lines selected for alterations in the function of the hyaluronan receptor CD44 show differences in glycosylation. J Exp Med 1995;182:431-7.
18. Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. Adv Immunol 1993;54:271-335.
19. Liu D, Liu T, Sy MS. Identification of two regions in the cytoplasmic domain of CD44 through which PMA, calcium, and foskolin differentially regulate the binding of CD44 to hyaluronic acid [in process citation]. Cell Immunol 1998;190:132-40.
20. Ue T, Yokozaki H, Kitadai Y, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998;79:127-32.
21. Weber GF, Ashkar S, Cantor H. Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Proc Assoc Am Physicians 1997;109:1-9.
22. Weber GF, Ashkar S, Glimcher MJ, et al. Receptor ligand interaction between CD44 and osteopontin (Eta-I). Science 1996;271:509-12.
23. Faassen AE, Schrager JA, Klein DJ, et al. A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44 is involved in type 1 collagen-mediated melanoma cell motility and invasion. J Cell Biol 1992;116 521-31.
24. Knutson JR, Iida J, Fields GB, et al. CD44 chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. Mol Biol Cell 1996;7:383-96.
25. Jalkanen S, Jalkanen M. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol 1992;116:817-25.
26. Toyama-Sorimachi N, Miyasaka M. A novel ligand for CD44 is sulfated proteoglycan. Int Immunol 1994;6:655-60.
27. Toyama-Sorimachi N, Sorimachi H, Tobita Y, et al. A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. Possible involvement in lymphoid cell adherence and activation. J Biol Chem 1995;270:7437-44.
28. Toyama-Sorimachi N, Kitamura F, Habuchi H, et al. Widespread expression of chondroitin sulfate-type serglycins with CD44 binding ability in hematopoietic cells. J Biol Chem 1997;272:26714-19.
29. Bennett KL, Jackson DG, Simon JC, et al. CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 1995;128:687-98.
30. Piepkorn M, Hovingh P, Bennett KL, et al. Chondroitin sulphate composition and structure in alternatively spliced CD44 fusion proteins. Biochem J 1997;327:499-506.
31. Lesley J, Kincade PW, Hyman R. Antibody-induced activation of the hyaluronan receptor function of CD44 requires multivalent binding by antibody, Eur J Immunol 1993;23:1902-9.
32. Sleeman J, Rudy W, Hoffmann M, et al. Regulated clustering of variant CD44 proteins increases their hyaluronate binding capacity. J Cell Biol 1996;135;1139-50.
33. Thomas L, Byers HR, Vink J, et al. CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol 1992;118:971-7.
34. Perschl A, Lesley J, English N, et al. Role of CD44 cytoplasmic domain in hyaluronan binding. Eur J Immunol 1995;25:495-501.
35. Xu FJ, Stack S, Boyer C, et al. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185 (c-erbB2): increased invasiveness may contribute to poor prognosis. Clin Cancer Res 1997;3:1629-31.
36. Bourguignon LY, Zhu H, Chu A, et al. Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem 1997;272:27913-18.
37. Burg MA, Grako KA, Stallcup WB. Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J Cell Physiol 1998;177:299-312
38. Bourguignon LYW, Zhu D, Zhu H. CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression [in process citation]. Front Biosci 1998;3:D637-49.
39. Lokeshwar VB, Fregien N, Bourguignon LY. Ankyrin-binding domain of CD44 (GP85) is required for the expression of hyaluronic acid-mediated adhesion function. J Cell Biol 1994;126:1099-109.
40. Zhu D, Bourguignon LY. The ankyrin-binding domain of CD44s is involved in regulating hyaluronic acid-mediated functions and prostate tumor cell transformation. Cell Motil Cytoskeleton 1998;39:209-22.
41. Bourguignon LY, Kalomiris EL, Lokeshwar VB. Acylation of the lymphoma transmembrane glycoprotein, GP85, may be required for GP85-ankyrin interaction. J Biol Chem 1991;266:11761-5.
42. 2+ and calmodulin. Implications for modulation of CD44 ankyrin interaction. J Biol Chem 1997;272:30322-8.
43. Liu D, Sy MS. A cysteine residue located in the transmembrane domain of CD44 is important in binding of CD44 to hyaluronic acid. J Exp Med 1996;183:1987-94.
44. Bourguignon LY, Gunja-Smith Z, Iida N, et al. CD44v (3,8 10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol 1999;176:206-15.
45. Tsukita S, Oishi K, Sato N, et al. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol 1994;126:391-401.
46. Yonemura S, Hirao M, Doi Y, et al. Ezrin/radixin/moesin (ERM) proteins hind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol 1998;140:885-95.
47. Legg JW, Isacke CM. Identification and functional analysis of the ezrin-binding site in the hyaluronan receptor, CD44 Curr Biol 1998;8:705-8.
48. Iida N, Bourguignon LY. New CD44 splice variants associated with human breast cancers. J Cell Physiol 1995;162:127-33.
49. Stauder R, Eisterer W, Thaler J, et al. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood 1995;85:2985-99.
50. Salles G, Zain M, Jiang WM, et al. Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. Blood 1993;82:3539-47.
51. Arch R, Wirth K, Hofmann M, et al. Participation in normal immune responses of a metastasis-inducing splice variant of CD44 [see comments]. Science 1992;257:682-5.
52. Terpe HJ, Stark H, Prehm P. et al. CD44 variant isoforms are preferentially expressed in basal epithelial of non-malignant human fetal and adult tissues. Histochemistry 1991;101:79-89.
53. Gansauge F, Gansauge S, Zobywalski A, et al. Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas. Cancer Res 1995;55:5499-503.
54. Hong RL, Pu YS, Chu JS, et al. Correlation of expression of CD44 isoforms and E-cadherin with differentiation in human urothelial cell lines and transitional cell carcinoma. Cancer Lett 1995;89:81-7.
55. Southgate J, Trejdosiewicz LK, Smith B, et al. Patterns of splice variant CD44 expression by normal human urothelium in situ and in vitro and by bladder-carcinoma cell lines. Int Cancer 1995;62:449-56.
56. Mackay CR, Terpe HJ, Stauder R, et al. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994;124:71-82.
57. Alho AM, Underhill CB. The hyaluronate receptor is preferentially expressed on proliferating epithelial cells. J Cell Biol 1989;108:1557-65.
58. Jain M, He Q, Lee WS, et al. Role of CD44 in the reaction of vascular smooth muscle cells to arterial wall injury. J Clin Invest 1996;98:877.
59. Trochon V, Mabilat C, Bertrand P, et al. Evidence of involvement of CD44 in endothelial cell proliferation migration and angiogenesis in vitro. Int J Cancer 1996;66:661-8.
60. Sherman L, Sleeman I, Dall P, et al. The CD44 proteins in embryonic development and in cancer. Curr Top Microbiol Immunol 1996;213:249-69.
61. Wainwright D, Sherman L, Sleeman J, et al. A splice variant of CD44 expressed in the rat apical ectodermal ridge contributes to limb outgrowth. Ann NY Acad Sci 1996;785:345-9.
62. Cooper DL, Dougherty GJ. To metastasize or not? Selection of CD44 splice sites. Nat Med 1995;1:635-7.
63. Green SJ, Tarone G, Underhill CB. Aggregation of macrophages and fibroblasts is inhibited by a monoclonal antibody to the hyaluronate receptor. Exp Cell Res 1988;178:224-32.
64. Underhill C, Dorfman A. The role of hyaluronic acid in intercellular adhesion of cultured mouse cells. Exp Cell Res 1978;117:155-64.
65. McKee CM, Penno MB, Cowman M, et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest 1996;98:2403-13.
66. DeGrendele HC, Kosfiszer M, Estess P, et al. CD44 activation and associated primary adhesion is inducible via T cell receptor stimulation. J Immunol 1997;59:2549-53.
67. DeGrendele HC, Estess P, Siegelman MH. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 1997;278:672-5.
68. Estess P, DeGrendele HC, Pascual V, et al. Functional activation of lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity [see comments]. J Clin Invest 1998;102:1173-82.
69. Mohamadzadeh M, DeGrendele H, Arizpe H, et al. Proinflammatory stimuli regulate endothelial hyaluronan expression and CD44/HA-dependent primary adhesion. J Clin Invest 1998;101:97-108
70. Weiss JM, Renkl AC, Sleeman J, et al. CD44 variant isoforms are essential for the function of epidermal Langerhans cells and dendritic cells [in process citation]. Cell Adhes Commun 1998;6:157-60.
71. Stamenkovic I, Amiot M, Pesando JM, et al. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 1989;56:1057-62.
72. Stamenkovic I, Aruffo A, Arniot M, et al. The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J 1991;10:343-8.
73. Birch M, Mitchell S, Hart IR. Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res 1901;151:6660-7.
74. Sy MS, Gun YJ, Stamenkovic I. Distinct effects of two CD44 isoforms on tumor growth in vivo. Exp Med 1991;174:859-66.
75. Sy MS, Guo YJ, Stamenkovic I. Inhibition of tumor growth in vivo with a soluble CD44 immunoglobulin fusion protein. J Exp Med 1992;176:623-7.
76. Zawadzki V, Perschl A, Rosel M, et al. Blockade of metastasis formation by CD44-receptor globulin. Int J Cancer 1998;75:919-24.
77. Bartolazzi A, Peach R, Aruffo A, et al. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med 1994;180:53-66.
78. Zeng C, Toole BP, Kinney SD, et al. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer 1998;77:396-401.
79. Yu Q, Toole BP, Stamenkovic I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. Exp Med 1997;186:1985-96.
80. Henke C, Bitterman P, Roongta C, et al. Induction of fibrublast apoptosis by anti-CD44 antibody: implications for the treatment of fibroproliferative lung disease. Am J Pathol 1996;149:1639-50.
81. Ayroldi E, Cannarile L, Migliorati G, et al. CD44 (Pgp-1) inhibits CD3 and dexamethasone-induced apoptosis. Blood 1995;86:2672-8.
82. Bates RC, Elith CA, Thorne RF, et al. Engagement of variant CD44 confers resistance to anti-integrin antibody-mediated apoptosis in a colon carcinoma cell line. Cell Adhes Common 1998;6:21-38.
83. Galluzzo E, Albi N, Fiorucci S, et al. Involvement pi CD44 variant isoforms in hyaluronate adhesion by human activated T cells. Eur J Immunol 1995;25:2932-9.
84. Griffoen AW, Horst E, Heider KH, et al. Expression of CD44 splice variants during lymphocyte activation and tumor progression. Cell Adhes Commun 1994;2:195-200.
85. Gunthert U, Hufmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24.
86. Rudy W, Hoffmann M, Schwartz-Albiez R, et al. The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: Each one individually suffices in confer metastatic behavior. Cancer Res 1993;53:1262-8.
87. Seiter S, Arch R, Reber S, et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993;177:443-55.
88. Sleeman JP, Arming S, Moll JF, et al. Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells. Canter Res 1996;56:3134-41.
89. Reeder JA, Gotley DC, Walsh MD, et al. Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment. Cancer Res 1998;58:3719-26.
90. Moll J, Schmidt A, van der Putten H, et al. Accelerated immune response in transgenic mice expressing rat CD44v4 v7 on T cells. J Immunol 1996;156;2085-94.
91. Driessens MH, Stroeken PJ, Rodriguez Erena NF, et al. Targeted disruption of CD44 in MDAY-D2 lymphosarcoma cells has no effect on subcutaneous growth or metastatic capacity. J Cell Biol 1995;131:1849-55.
92. Givehchian M, Worner S, Strater J, et al. No evidence for cancer-related CD44 splice variants in primary and metastatic colorectal cancer. Eur J Cancer 1998;34:1099-104.
93. Zahalka MA, Okon E, Gosslar U, et al. Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent. J Immunol 1995;154:5345-55.
94. Matsumura Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation [see comments]. Lancet 1992;340:1053-8.
95. Goodison S, Tarin D. Clinical implications of anomalous CD44 gene expression in neoplasia [in process citation]. Front Biosci 1998;3:E89-109.
96. Woodman AC, Sugiyama M, Yushida K, et al. Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoforms. Am J Pathol 1996;149:1519-30.
97. Sugino T, Gotham H, Yoshida K, et al. Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol 1996;149:873-82.
98. van Weering DH, Baas PD, Bos JL. A PCR-based method for the analysis of human CD44 splice products. PCR Methods Appl 1993;3:100-6.
99. Goodison S, Yoshida K, Sugino T, et al. Rapid analysis of distinctive CD44 RNA splicing preferences that characterize colonic tumors. Cancer Res 1997;57:3140-4
100. Gorham H, Sugino T, Woodman AC, et al. Cellular distribution of CD44 gene transcripts in colorectal carcinomas and in normal colonic mucosa. J Clin Pathol 1996;49:182-8.
101. Matsumura Y, Hanbury D, Smith J, et al. Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells. BMJ 1994;308:619-24.
102. Matsumura Y, Sugiyama M, Matsumura S, et al. Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities. J Pathol 1995;177:11-20.
103. Yoshida K, Bolodeoku J, Sugino T, et al. Abnormal retention of intron 9 in CD44 gene transcripts in human gastrointestinal tumors. Cancer Res 1995;55:1273-7.
104. Katoh S, McCarthy JB, Kincade PW. Characterization of soluble CD44 in the circulation of mice. Levels are affected by immune activity and tumor growth. J Immunol 1994;153:3440-9.
105. Ristamaki R, Joensuu H, Jalkanen S. Does soluble CD44 reflect the clinical behavior of human cancer? Curr Top Microbiol Immunol 1996;213:155-66.
106. De Rossi G, Marroni P, Paganuzzi M, et al. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, B cell chronic lymphocytic leukemia. Leukemia 1997;11:134-41.
107. Bolodeoku J, Yoshida K, Sugino T, et al. CD44 expression in human breast cancer cell lines is related to oestrogen receptor (ER) status and confluency in vitro. Biochem Soc Trans 1997;25:3565.
108. Goodison S, Yoshida K, Churchman M, et al. Multiple intron retention occurs in tumor cell CD44 mRNA processing. Am.J Pathol 1998;153:1221-8.
109. Konig H, Moll J, Ponta H, et al. Trans-acting factors regulate the expression of CD44 splice variants. EMBO 1996;15:4030-9.
110. Konig H, Poma H, Herrlich P. Coupling of signal transduction to alternative pre-mRNA splicing by a composite splice regulator. EMBO J 1998;17:2904-13.
111. Sugino T, Yoshida K, Zhao S, et al. Disorderly CD44 gene expression in human cancer cells can be modulated by growth conditions [in process citation]. J Pathol 1999;186:17-23.
112. Kogerman P, Sy MS, Culp LA. Over-expression of human CD44 in murine 3T3 cells: selection against during primary tumorigenesis and selection liar during micrometastasis. Clin Exp Metastasis 1998;16:83-93.
113. Kogerman P, Sy MS, Culp LA. CD44 protein levels and its biological activity are regulated in Balb/c 3T3 fibrolasts by serum factors and by transformation with the ras but not with the sis oncogene. J Cell Physiol 1996;169:341-9.
114. Kogerman P, Sy MS, Culp LA. Oncogene-dependent expression of CD44 in Balb/c 3T3 derivatives; correlation with metastatic competence. Clin Exp Metastasis 1996;14:73-82.